This Article Full Text Full Text (PDF) All Versions of this Article: 44/5/751    most recent 01.HYP.0000144466.11568.7ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barbato, J. C. Articles by Franco-Saenz, R. Search for Related Content PubMed PubMed Citation Articles by Barbato, J. C. Articles by Franco-Saenz, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL POTASSIUM SPIRONOLACTONE Related Collections Contractile function Cardio-renal physiology/pathophysiology Congestive

(Hypertension. 2004;44:751.)
© 2004 American Heart Association, Inc.

Scientific Contributions

Mechanisms for Aldosterone and Spironolactone-Induced Positive Inotropic Actions in the Rat Heart

John C. Barbato; Sumia Rashid; Patrick J. Mulrow; Joseph I. Shapiro; Roberto Franco-Saenz^*

From the Department of Medicine, Medical College of Ohio, Toledo.

Correspondence to Joseph I. Shapiro, MD, Department of Medicine, Medical College of Ohio, 3120 Glendale Avenue, Toledo, OH 43614. E-mail jshapiro{at}mco.edu

Previously, we reported that aldosterone and spironolactone have inotropic effects in the isolated perfused heart. To address the mechanisms underlying these inotropic effects, we examined the effects of aldosterone and spironolactone on isolated cardiac myocyte shortening, intracellular calcium ([Ca⁺²]_i), pHi, and calcium-dependent actinomyosin ATPase activity. Aldosterone significantly increased shortening in cardiac myocytes (8.0±1.0 versus 16.0±1.3%, P<0.01) but neither diastolic [Ca⁺²]_i (61.0±1.1 versus 66.0±4.4 nmol/L) nor peak systolic [Ca⁺²]_i (302±11 versus 304±17 nmol/L) was affected. Spironolactone-increased shortening was also not coupled with changes in peak systolic calcium; however, diastolic calcium was significantly increased by spironolactone. Aldosterone, but not spironolactone, increased pHi from 7.23±0.03 to 7.59±0.02 (P<0.01); this was completely blocked by coadministration of 100 µmol/L of ethyl-isopropyl amiloride (EIPA), an inhibitor of the Na⁺/H⁺ exchanger (P<0.01). Consistent with this finding, aldosterone increased cytosolic sodium concentration ([Na⁺]_i) from 9.2±0.15 to 11.4±0.2 mmol/L and produced a leftward shift in the pCa ATPase curve (pCa=5.82±0.02 versus 6.35±0.02, P<0.01) without affecting maximal myosin ATPase activity. Conversely, spironolactone, but not aldosterone, significantly increases maximal actomyosin ATPase activity (837±59 versus 355±52 nmol inorganic phosphate (P_i) · min^–1 · g tissue^–1). Collectively, these data strongly suggest that the inotropic actions of aldosterone and spironolactone are caused by different mechanisms of action. Aldosterone appeared to increase inotropy primarily through increased cytosolic pH, whereas spironolactone increased myosin ATPase calcium sensitivity and diastolic calcium concentration.

Key Words: mineralocorticoid • cardiac function • heart failure • calcium

This article has been cited by other articles:

				W. Chai, I. M. Garrelds, R. de Vries, and A.H. Jan Danser Cardioprotective Effects of Eplerenone in the Rat Heart: Interaction With Locally Synthesized or Blood-Derived Aldosterone? Hypertension, April 1, 2006; 47(4): 665 - 670. [Abstract] [Full Text] [PDF]

				P. J. Fuller and M. J. Young Mechanisms of Mineralocorticoid Action Hypertension, December 1, 2005; 46(6): 1227 - 1235. [Abstract] [Full Text] [PDF]

				R. Perrier, S. Richard, Y. Sainte-Marie, B. C. Rossier, F. Jaisser, E. Hummler, and J.-P. Benitah A direct relationship between plasma aldosterone and cardiac L-type Ca2+ current in mice J. Physiol., November 15, 2005; 569(1): 153 - 162. [Abstract] [Full Text] [PDF]

				W. Chai, I. M. Garrelds, R. de Vries, W. W. Batenburg, J. P. van Kats, and A.H. Jan Danser Nongenomic Effects of Aldosterone in the Human Heart: Interaction With Angiotensin II Hypertension, October 1, 2005; 46(4): 701 - 706. [Abstract] [Full Text] [PDF]